{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:09Z","timestamp":1786951449966,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01327-3","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:19:42Z","timestamp":1786025982000},"page":"1225-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer\u2019s Disease: A Systematic Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3593-2601","authenticated-orcid":false,"given":"Sirikalaya","family":"Brimson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-4073","authenticated-orcid":false,"given":"Premrutai","family":"Thitilertdecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0693-6366","authenticated-orcid":false,"given":"Kishoree Krishna","family":"Kumaree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-8262","authenticated-orcid":false,"given":"James Michael","family":"Brimson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"4","key":"1327_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.psc.2022.07.003","volume":"45","author":"BC Yarns","year":"2022","unstructured":"Yarns BC, Holiday KA, Carlson DM, Cosgrove CK, Melrose RJ. Pathophysiology of Alzheimer\u2019s disease. Psychiatr Clin N Am. 2022;45(4):663\u201376. https:\/\/doi.org\/10.1016\/j.psc.2022.07.003.","journal-title":"Psychiatr Clin N Am"},{"key":"1327_CR2","doi-asserted-by":"publisher","unstructured":"Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195\u2013203. https:\/\/doi.org\/10.1016\/j.pharep.2014.09.004.","DOI":"10.1016\/j.pharep.2014.09.004"},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-981-13-9636-6_2","volume-title":"Biological, diagnostic and therapeutic advances in Alzheimer's disease: non-pharmacological therapies for alzheimer's disease","author":"F Amin","year":"2019","unstructured":"Amin F, Shamsi A, Asghar MN, Khaki PSS, Khan MS, Tabrez S, et al. Alzheimer\u2019s: a progressive brain disease: causes, symptoms, and prevention. In: Ashraf GM, Alexiou A, editors., et al., Biological, diagnostic and therapeutic advances in Alzheimer\u2019s disease: non-pharmacological therapies for alzheimer\u2019s disease. Singapore: Springer Singapore; 2019. p. 31\u201351. https:\/\/doi.org\/10.1007\/978-981-13-9636-6_2."},{"issue":"1","key":"1327_CR4","doi-asserted-by":"publisher","first-page":"43242","DOI":"10.1038\/s41598-025-27360-8","volume":"15","author":"J Shetty","year":"2025","unstructured":"Shetty J, Shenoy MK, Kolekar SV, Prabhu MM, Kotha RR, Bhardwaj S. Early detection of Alzheimer\u2019s disease progression: comparative evaluation of deep learning models. Sci Rep. 2025;15(1):43242. https:\/\/doi.org\/10.1038\/s41598-025-27360-8.","journal-title":"Sci Rep."},{"issue":"1","key":"1327_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Cd005593","volume":"25","author":"J Birks","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;25(1):Cd005593. https:\/\/doi.org\/10.1002\/14651858.Cd005593.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1327_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"R Khoury","year":"2018","unstructured":"Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine. Ther Adv Drug Saf. 2018;9(3):171\u20138. https:\/\/doi.org\/10.1177\/2042098617750555.","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"1327_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-170672","volume":"62","author":"J Folch","year":"2018","unstructured":"Folch J, Busquets O, Ettcheto M, S\u00e1nchez-L\u00f3pez E, Castro-Torres RD, Verdaguer E, et al. Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis. 2018;62(3):1223\u201340. https:\/\/doi.org\/10.3233\/JAD-170672.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1327_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317\u201324. https:\/\/doi.org\/10.1001\/jama.291.3.317.","journal-title":"JAMA"},{"issue":"2","key":"1327_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"1327_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/jci154889","author":"ES Musiek","year":"2021","unstructured":"Musiek ES, Gomez-Isla T, Holtzman DM. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. J Clin Investig. 2021. https:\/\/doi.org\/10.1172\/jci154889.","journal-title":"J Clin Investig"},{"issue":"3","key":"1327_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","volume":"23","author":"A Rahman","year":"2023","unstructured":"Rahman A, Hossen MA, Chowdhury MFI, Bari S, Tamanna N, Sultana SS, et al. Aducanumab for the treatment of Alzheimer\u2019s disease: a systematic review. Psychogeriatrics. 2023;23(3):512\u201322. https:\/\/doi.org\/10.1111\/psyg.12944.","journal-title":"Psychogeriatrics"},{"issue":"1","key":"1327_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1327_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/s1474-4422(19)30480-6","volume":"19","author":"L Schneider","year":"2020","unstructured":"Schneider L. A resurrection of aducanumab for Alzheimer\u2019s disease. Lancet Neurol. 2020;19(2):111\u20132. https:\/\/doi.org\/10.1016\/s1474-4422(19)30480-6.","journal-title":"Lancet Neurol"},{"issue":"7618","key":"1327_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"key":"1327_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/cia.S325026","volume":"17","author":"M Vaz","year":"2022","unstructured":"Vaz M, Silva V, Monteiro C, Silvestre S. Role of aducanumab in the treatment of Alzheimer\u2019s disease: challenges and opportunities. Clin Interv Aging. 2022;17:797\u2013810. https:\/\/doi.org\/10.2147\/cia.S325026.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"1327_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, Aducanumab, and Gantenerumab\u2014binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20(1):195\u2013206. https:\/\/doi.org\/10.1007\/s13311-022-01308-6.","journal-title":"Neurotherapeutics"},{"key":"1327_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"18","key":"1327_CR18","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"issue":"5","key":"1327_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","volume":"79","author":"EL Ross","year":"2022","unstructured":"Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and Donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478\u201387. https:\/\/doi.org\/10.1001\/jamaneurol.2022.0315.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1327_CR20","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14728222.2020.1805435","volume":"24","author":"JM Brimson","year":"2020","unstructured":"Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets. 2020;24(10):1009\u201328. https:\/\/doi.org\/10.1080\/14728222.2020.1805435.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"1327_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cns.70919","volume":"32","author":"J Jung","year":"2026","unstructured":"Jung J, Kim Y, Cirunduzi AC, Yoon S, Bang S, Yang SH. Multi\u2010target\u2010directed ligands (MTDLs) as potential therapeutic candidates targeting multiple pathogenic factor of Alzheimer\u2019s disease. CNS Neurosci Ther. 2026;32(5):e70919. https:\/\/doi.org\/10.1002\/cns.70919.","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"1327_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-023-01007-6","volume":"37","author":"DS Malar","year":"2023","unstructured":"Malar DS, Thitilertdecha P, Ruckvongacheep KS, Brimson S, Tencomnao T, Brimson JM. Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders. CNS Drugs. 2023;37(5):399\u2013440. https:\/\/doi.org\/10.1007\/s40263-023-01007-6.","journal-title":"CNS Drugs"},{"key":"1327_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-12457-1_28","author":"B Delprat","year":"2020","unstructured":"Delprat B, Crouzier L, Su T-P, Maurice T. At the crossing of ER stress and MAMs: a key role of sigma-1 receptor? Calcium Signal. 2020. https:\/\/doi.org\/10.1007\/978-3-030-12457-1_28.","journal-title":"Calcium Signal"},{"issue":"3","key":"1327_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1124\/jpet.106.107557","volume":"319","author":"C Katnik","year":"2006","unstructured":"Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther. 2006;319(3):1355\u201365. https:\/\/doi.org\/10.1124\/jpet.106.107557.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1327_CR25","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1167\/iovs.16-19199","volume":"58","author":"DZ Ellis","year":"2017","unstructured":"Ellis DZ, Li L, Park Y, He S, Mueller B, Yorio T. Sigma-1 receptor regulates mitochondrial function in glucose-and oxygen-deprived retinal ganglion cells. Investig Ophthalmol Vis Sci. 2017;58(5):2755\u201364. https:\/\/doi.org\/10.1167\/iovs.16-19199.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"1327_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14728222.2021.1939681","volume":"25","author":"MI Prasanth","year":"2021","unstructured":"Prasanth MI, Malar D, Tencomnao T, Brimson J. The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer\u2019s disease. Expert Opin Ther Targets. 2021;25(6):435\u201349. https:\/\/doi.org\/10.1080\/14728222.2021.1939681.","journal-title":"Expert Opin Ther Targets"},{"key":"1327_CR27","doi-asserted-by":"publisher","unstructured":"Linciano P, Sorbi C, Rossino G, Rossi D, Marsala A, Denora N, et al. Novel S1R agonists counteracting NMDA excitotoxicity and oxidative stress: a step forward in the discovery of neuroprotective agents. Eur J Med Chem 2023;249:115163. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115163.","DOI":"10.1016\/j.ejmech.2023.115163"},{"issue":"1","key":"1327_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1570159x15666170529104323","volume":"16","author":"B Penke","year":"2018","unstructured":"Penke B, Fulop L, Szucs M, Frecska E. The role of sigma-1 receptor, an intracellular chaperone in neurodegenerative diseases. Curr Neuropharmacol. 2018;16(1):97\u2013116. https:\/\/doi.org\/10.2174\/1570159x15666170529104323.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"1327_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12149-007-0094-z","volume":"22","author":"M Mishina","year":"2008","unstructured":"Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K-i, et al. Low density of sigma 1 receptors in early Alzheimer\u2019s disease. Ann Nucl Med. 2008;22(3):151\u20136. https:\/\/doi.org\/10.1007\/s12149-007-0094-z.","journal-title":"Ann Nucl Med"},{"issue":"658","key":"1327_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk1051","volume":"14","author":"AV Venkataraman","year":"2022","unstructured":"Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, et al. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer\u2019s disease. Sci Transl Med. 2022;14(658):eabk1051. https:\/\/doi.org\/10.1126\/scitranslmed.abk1051.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1327_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0006-8993(93)91441-t","volume":"623","author":"KLR Jansen","year":"1993","unstructured":"Jansen KLR, Faull RLM, Storey P, Leslie RA. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer\u2019s disease correlates with CA1 pyramidal cell loss. Brain Res. 1993;623(2):299\u2013302. https:\/\/doi.org\/10.1016\/0006-8993(93)91441-t.","journal-title":"Brain Res"},{"issue":"12","key":"1327_CR32","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1176\/appi.ajgp.13.12.1062","volume":"13","author":"N Uchida","year":"2005","unstructured":"Uchida N, Ujike H, Tanaka Y, Sakai A, Yamamoto M, Fujisawa Y, et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(12):1062\u20136. https:\/\/doi.org\/10.1176\/appi.ajgp.13.12.1062.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"1327_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000101990","volume":"23","author":"A Maruszak","year":"2007","unstructured":"Maruszak A, Safranow K, Gacia M, Gabryelewicz T, S\u0142owik A, Styczy\u0144ska M, et al. Sigma receptor type 1 gene expression variation in a group of polish patients with Alzheimer\u2019s disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(6):432\u20138. https:\/\/doi.org\/10.1159\/000101990.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"1327_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neulet.2012.04.046","volume":"517","author":"\u00c1 Feh\u00e9r","year":"2012","unstructured":"Feh\u00e9r \u00c1, Juh\u00e1sz A, L\u00e1szl\u00f3 A, K\u00e1lm\u00e1n J Jr, P\u00e1k\u00e1ski M, K\u00e1lm\u00e1n J, et al. Association between a variant of the sigma-1 receptor gene and Alzheimer\u2019s disease. Neurosci Lett. 2012;517(2):136\u20139. https:\/\/doi.org\/10.1016\/j.neulet.2012.04.046.","journal-title":"Neurosci Lett"},{"key":"1327_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2025.138349","author":"T Maurice","year":"2025","unstructured":"Maurice T. Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer\u2019s disease model. Neurosci Lett. 2025. https:\/\/doi.org\/10.1016\/j.neulet.2025.138349.","journal-title":"Neurosci Lett"},{"key":"1327_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1838483","author":"T Maurice","year":"2020","unstructured":"Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2020. https:\/\/doi.org\/10.1080\/17460441.2021.1838483.","journal-title":"Expert Opin Drug Discov"},{"key":"1327_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113287","author":"MW Baeken","year":"2025","unstructured":"Baeken MW, Christ M, Schmitt D, Trein W, Nagel H, Clement AM, et al. Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP. iScience. 2025. https:\/\/doi.org\/10.1016\/j.isci.2025.113287.","journal-title":"iScience"},{"key":"1327_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fncel.2014.00463","volume":"8","author":"V Lahmy","year":"2015","unstructured":"Lahmy V, Long R, Morin D, Villard V, Maurice T. Mitochondrial protection by the mixed muscarinic\/\u03c31 ligand ANAVEX 2\u201373, a tetrahydrofuran derivative, in A\u03b225\u201335 peptide-injected mice, a nontransgenic Alzheimer\u2019s disease model. Front Cell Neurosci. 2015;8:463. https:\/\/doi.org\/10.3389\/fncel.2014.00463.","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"1327_CR39","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0269881110379286","volume":"25","author":"V Villard","year":"2011","unstructured":"Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma1 (\u03c31) ligand ANAVEX 2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25(8):1101\u201317. https:\/\/doi.org\/10.1177\/0269881110379286.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1327_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12013","volume":"6","author":"H Hampel","year":"2020","unstructured":"Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer\u2019s disease therapy: analysis of the blarcamesine (ANAVEX 2\u201073) phase 2a clinical study. Alzheimers Dement Transl Res Clin Interv. 2020;6(1):e12013. https:\/\/doi.org\/10.1002\/trc2.12013.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"1327_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1327_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"Suppl B","key":"1327_CR43","first-page":"1","volume":"12","author":"O Voges","year":"2014","unstructured":"Voges O, Weigmann I, Bitterlich N, Missling C, Schindler C. A Phase I dose escalation study to investigate safety, tolerability, and pharmacokinetics of ANAVEX 2\u201373 in healthy male subjects. Innov Clin Neurosci. 2014;12(Suppl B):1\u201320.","journal-title":"Innov Clin Neurosci."},{"issue":"7S_Part_24","key":"1327_CR44","doi-asserted-by":"publisher","first-page":"P1174","DOI":"10.1016\/j.jalz.2016.07.101","volume":"12","author":"S Macfarlane","year":"2016","unstructured":"Macfarlane S, Cecchi M, Moore D, Maruff P, Zografidis T, Missling C. P4-356: safety and efficacy 31 week data of Anavex 2-73 in a phase 2A study in mild-moderate Alzheimer\u2019s disease patients. Alzheimers Dement. 2016;12(7S_Part_24):P1174. https:\/\/doi.org\/10.1016\/j.jalz.2016.07.101.","journal-title":"Alzheimers Dement"},{"issue":"7S_Part_19","key":"1327_CR45","doi-asserted-by":"publisher","first-page":"P900","DOI":"10.1016\/j.jalz.2015.08.130","volume":"11","author":"S Macfarlane","year":"2015","unstructured":"Macfarlane S, Cecchi M, Moore D, Zografidis T, Missling C. P4-300: new exploratory Alzheimer\u2019s drug anavex 2-73 changes in electrophysiological markers in Alzheimer\u2019s disease: first patient data from an ongoing phase 2a study in mild-to-moderate Alzheimer\u2019s patients. Alzheimers Dement. 2015;11(7S_Part_19):P900. https:\/\/doi.org\/10.1016\/j.jalz.2015.08.130.","journal-title":"Alzheimers Dement"},{"key":"1327_CR46","doi-asserted-by":"publisher","unstructured":"Parmentier F, Etcheto A, Missling C, Williams C, Afshar M. O4-02-04: exploring gut microbiota as a source of potential biomarkers: initial results from the Anavex\u00ae 2\u201373 Alzheimer's disease clinical study. Alzheimer's Dementia. 2019;15(7S_Part_23):P1232-P3. https:\/\/doi.org\/10.1016\/j.jalz.2019.06.4749.","DOI":"10.1016\/j.jalz.2019.06.4749"},{"issue":"1","key":"1327_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane S, Grimmer T, Teo K, O\u2019Brien TJ, Woodward M, Grunfeld J, et al. Blarcamesine for the treatment of early Alzheimer\u2019s disease: results from the ANAVEX 2-73-AD-004 phase IIB\/III trial. J Prev Alzheimers Dis. 2025;12(1):100016. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100016.","journal-title":"J Prev Alzheimers Dis"},{"issue":"S6","key":"1327_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/alz.090729","volume":"20","author":"MN Sabbagh","year":"2024","unstructured":"Sabbagh MN, Chezem WR, Jin K, Missling CU, Group ALSR. Blarcamesine in early Alzheimer disease phase 2b\/3 randomized clinical trial. Alzheimers Dement. 2024;20(S6):e090729. https:\/\/doi.org\/10.1002\/alz.090729.","journal-title":"Alzheimers Dement"},{"key":"1327_CR49","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.27.25336656","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane S, Grimmer T, Teo K, O\u2019Brien TJ, Woodward M, Grunfeld J, et al. Oral blarcamesine Phase IIb\/III trial confirms identified precision medicine patient population\u2014significant broad clinical and quality of life improvements for early Alzheimer\u2019s disease patients. medRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.09.27.25336656.","journal-title":"medRxiv."},{"issue":"S5","key":"1327_CR50","doi-asserted-by":"publisher","first-page":"e106527","DOI":"10.1002\/alz70859_106527","volume":"21","author":"MN Sabbagh","year":"2025","unstructured":"Sabbagh MN, Gabelle A, Grimmer T, Villa L, Gordon E, Borrot M, et al. Precision medicine in Alzheimer\u2019s disease (AD): observed efficacy treatment effects from blarcamesine clinical AD trials. Alzheimer\u2019s Dement. 2025;21(S5):e106527. https:\/\/doi.org\/10.1002\/alz70859_106527.","journal-title":"Alzheimer's Dement"},{"key":"1327_CR51","unstructured":"Liedtke WB, Chezem W, Gould D, Tran J, Lopez-Talavera JC, Jin K, et al. COL24A1 gene impacts effectiveness of autophagy-enhancing blarcamesine in earlyAlzheimer's disease. 2026 (unpublished).https:\/\/www.neurologylive.com\/view\/oral-blarcamesine-reduces-cognitive-decline-phase-2b-3-trial-early-ad. Accessed on Nov 1st 2025."},{"issue":"S5","key":"1327_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/alz70859_101346","volume":"21","author":"MN Sabbagh","year":"2025","unstructured":"Sabbagh MN, Macfarlane S, Gabelle A, Grimmer T, Jin K, Chezem WR, et al. Phase IIb\/III ATTENTION-AD study: over three years of continuous treatment with oral Blarcamesine continues to significantly benefit early Alzheimer\u2019s disease patients. Alzheimers Dement. 2025;21(S5):e101346. https:\/\/doi.org\/10.1002\/alz70859_101346.","journal-title":"Alzheimers Dement"},{"issue":"S7","key":"1327_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.059024","volume":"19","author":"C Williams","year":"2023","unstructured":"Williams C, Kindermans M, Parmentier F, Goodsaid F, Hammond E, Missling CU, et al. Study of the mechanism of action of Blarcamesine (ANAVEX\u00ae2-73): whole blood transcriptomics analysis identifies treatment impact on compensatory pathways by restoring key neurodegenerative pathways functionality, including Alzheimer\u2019s disease pathway. Alzheimers Dement. 2023;19(S7):e059024. https:\/\/doi.org\/10.1002\/alz.059024.","journal-title":"Alzheimers Dement"},{"key":"1327_CR54","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbr.2015.09.020","volume":"296","author":"T Maurice","year":"2016","unstructured":"Maurice T. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res. 2016;296:270\u20138. https:\/\/doi.org\/10.1016\/j.bbr.2015.09.020.","journal-title":"Behav Brain Res"},{"key":"1327_CR55","unstructured":"European_Medicines_Agency. Withdrawal of application for the marketing authorisation of Blarcamesine Anavex (blarcamesine). 2026 [cited 2026 1 July]. https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_en.pdf. Accessed on June 30th 2026."},{"key":"1327_CR56","unstructured":"Anavex Life Sciences Corp. A phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ANAVEX 2-73 for cognitive impairment in patients with Parkinson's disease with dementia. 2018 [cited 2026 15\/01\/2026]. https:\/\/clinicaltrials.gov\/study\/NCT03774459. Accessed on Oct 1st 2025."},{"key":"1327_CR57","unstructured":"Anavex Life Sciences Corp. Open label extension study for patients with Parkinson's Disease with dementia enrolled in study ANAVEX 2-73-PDD-001. 2020 2022-08-01 [cited 15\/01\/2026]. https:\/\/clinicaltrials.gov\/study\/NCT04575259. Accessed on Oct 1st 2025."},{"key":"1327_CR58","unstructured":"Anavex Life Sciences Corp. Study of ANAVEX 2-73 in patients with Rett syndrome. 2019 [cited 2026 26\/06\/2026]. https:\/\/clinicaltrials.gov\/study\/NCT03758924. Accessed on Oct 1st 2025."},{"key":"1327_CR59","unstructured":"Anavex Life Sciences Corp. A double-blind, randomized, placebo-controlled, safety and efficacy study of ANAVEX 2-73 in patients With Rett syndrome. 2019 2022 [cited 14\/01\/2026]. https:\/\/clinicaltrials.gov\/study\/NCT03941444. Accessed on Oct 1st 2025."},{"key":"1327_CR60","unstructured":"Anavex_Life_Sciences Corp. ANAVEX 2-73 study in pediatric patients with Rett syndrome (EXCELLENCE). 2020 [cited 2026 26\/01\/2026]. https:\/\/clinicaltrials.gov\/study\/NCT04304482. Accessed on Oct 1st 2025."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01327-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:28:33Z","timestamp":1786948113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01327-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01327-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data collected and curated in this study are freely available online or from the authors upon reasonable request.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this article.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this article.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this article.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this article.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualisation: SB, JMB; Data collection JMB, SB, PT; Data analysis JMB, KKK; Drafting manuscript SB, JMB, KKK, PT; Editing manuscript JMB, SB, PT; Preparation of figures JMB; All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}